-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Capital Markets Maintains Market Outperform on Structure Therapeutics, Lowers Price Target to $87

Benzinga·02/28/2025 15:48:16
Listen to the news
Citizens Capital Markets analyst Jonathan Wolleben maintains Structure Therapeutics (NASDAQ:GPCR) with a Market Outperform and lowers the price target from $91 to $87.